![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TCEAL2 |
Gene summary for TCEAL2 |
![]() |
Gene information | Species | Human | Gene symbol | TCEAL2 | Gene ID | 140597 |
Gene name | transcription elongation factor A like 2 | |
Gene Alias | MY0876G05 | |
Cytomap | Xq22.1 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9H3H9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
140597 | TCEAL2 | PTCwithHT_6 | Human | Thyroid | HT | 1.01e-02 | -2.52e-01 | 0.02 |
140597 | TCEAL2 | PTCwithoutHT_2 | Human | Thyroid | PTC | 1.78e-02 | -2.37e-01 | 0.0419 |
140597 | TCEAL2 | PTC07 | Human | Thyroid | PTC | 2.41e-02 | 3.23e-01 | 0.2044 |
140597 | TCEAL2 | ATC12 | Human | Thyroid | ATC | 2.66e-05 | -2.66e-01 | 0.34 |
140597 | TCEAL2 | ATC13 | Human | Thyroid | ATC | 5.14e-03 | -2.66e-01 | 0.34 |
140597 | TCEAL2 | ATC4 | Human | Thyroid | ATC | 3.82e-05 | -2.66e-01 | 0.34 |
140597 | TCEAL2 | ATC5 | Human | Thyroid | ATC | 2.43e-03 | -2.66e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
TCEAL2 | MSC.MVA | Thyroid | ATC | CA4,CTD-2192J16.15,RP11-848P1.9, etc. | 4.78e-02 | ![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TCEAL2 | SNV | Missense_Mutation | c.472N>A | p.His158Asn | p.H158N | Q9H3H9 | protein_coding | deleterious(0.01) | possibly_damaging(0.75) | TCGA-A2-A0CW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
TCEAL2 | SNV | Missense_Mutation | c.106C>G | p.Leu36Val | p.L36V | Q9H3H9 | protein_coding | tolerated(0.41) | benign(0.165) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
TCEAL2 | SNV | Missense_Mutation | rs781303147 | c.106C>A | p.Leu36Met | p.L36M | Q9H3H9 | protein_coding | tolerated(0.13) | probably_damaging(0.966) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TCEAL2 | SNV | Missense_Mutation | novel | c.480N>T | p.Met160Ile | p.M160I | Q9H3H9 | protein_coding | tolerated(0.05) | benign(0.382) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TCEAL2 | SNV | Missense_Mutation | novel | c.476N>C | p.Asp159Ala | p.D159A | Q9H3H9 | protein_coding | deleterious(0.03) | probably_damaging(0.954) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TCEAL2 | insertion | In_Frame_Ins | novel | c.440_441insTCTCTT | p.Ala147_Gln148insLeuPhe | p.A147_Q148insLF | Q9H3H9 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
TCEAL2 | SNV | Missense_Mutation | novel | c.389N>A | p.Ala130Asp | p.A130D | Q9H3H9 | protein_coding | deleterious(0.01) | probably_damaging(0.975) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TCEAL2 | SNV | Missense_Mutation | novel | c.656N>T | p.Arg219Met | p.R219M | Q9H3H9 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TCEAL2 | SNV | Missense_Mutation | c.653G>A | p.Arg218Gln | p.R218Q | Q9H3H9 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AJ-A8CT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TCEAL2 | SNV | Missense_Mutation | c.382C>T | p.Arg128Cys | p.R128C | Q9H3H9 | protein_coding | tolerated(0.11) | probably_damaging(0.993) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |